Acute myelogenous leukemia: current treatment and future directions.
Acute myelogenous leukemia (AML), although an uncommon disorder, is a useful prototype for the treatment of malignancies in general. Significant advances have been made in both the understanding and treatment of this disease. In particular, clinically relevant molecular mechanisms of disease in AML are being defined that hold future therapeutic promise. We review the classification and biology of AML and the current treatment controversies in the use of chemotherapy and bone marrow transplantation, and suggest directions for future research.
Mastrianni
D M
DM
Hematology/Oncology Division, Beth Israel Hospital, Boston, Massachusetts 02115.
Tung
N M
NM
Tenen
D G
DG
D000208:Acute Disease; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D016026:Bone Marrow Transplantation / Q000379:methods; D007446:Chromosome Inversion; D005544:Forecasting; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use; D007951:Leukemia, Myeloid / Q000145:classification / Q000235:genetics / Q000628:therapy; D012074:Remission Induction / Q000379:methods; D014178:Translocation, Genetic; D014182:Transplantation, Autologous / Q000379:methods; D014184:Transplantation, Homologous / Q000379:methods
D007155:Immunologic Factors